Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | ATPase family, AAA domain containing 5 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | Get druggable targets OG5_139225 | All targets in OG5_139225 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | hexokinase, putative | 0.0421 | 0.2642 | 0.2642 |
Toxoplasma gondii | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Schistosoma mansoni | adenosylhomocysteinase | 0.0832 | 0.5915 | 0.5915 |
Brugia malayi | Hexokinase family protein | 0.0421 | 0.2642 | 0.2642 |
Entamoeba histolytica | hexokinase 2 | 0.0421 | 0.2642 | 0.2642 |
Onchocerca volvulus | 0.0421 | 0.2642 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0134 | 0.0351 | 0.0351 |
Trypanosoma brucei | S-adenosylhomocysteine hydrolase, putative | 0.1344 | 1 | 1 |
Plasmodium falciparum | adenosylhomocysteinase | 0.1344 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Brugia malayi | Hexokinase family protein | 0.013 | 0.0322 | 0.0322 |
Echinococcus multilocularis | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.1344 | 1 | 1 |
Onchocerca volvulus | 0.0421 | 0.2642 | 1 | |
Echinococcus granulosus | geminin | 0.0205 | 0.0915 | 0.0915 |
Echinococcus multilocularis | atpase aaa+ type core atpase aaa type core | 0.0979 | 0.7093 | 0.7093 |
Loa Loa (eye worm) | hexokinase | 0.0264 | 0.139 | 0.139 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0915 | 0.0915 |
Echinococcus multilocularis | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Leishmania major | S-adenosylhomocysteine hydrolase | 0.1344 | 1 | 1 |
Schistosoma mansoni | adenosylhomocysteinase | 0.0832 | 0.5915 | 0.5915 |
Schistosoma mansoni | adenosylhomocysteinase | 0.0832 | 0.5915 | 0.5915 |
Plasmodium vivax | hexokinase, putative | 0.0421 | 0.2642 | 0.2642 |
Onchocerca volvulus | 0.0421 | 0.2642 | 1 | |
Loa Loa (eye worm) | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.0422 | 0.2647 | 0.2647 |
Loa Loa (eye worm) | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Entamoeba histolytica | adenosylhomocysteinase, putative | 0.1344 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Loa Loa (eye worm) | hypothetical protein | 0.0287 | 0.1574 | 0.1574 |
Toxoplasma gondii | adenosylhomocysteinase, putative | 0.1344 | 1 | 1 |
Echinococcus multilocularis | geminin | 0.0205 | 0.0915 | 0.0915 |
Echinococcus granulosus | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Brugia malayi | hexokinase type II | 0.0134 | 0.0351 | 0.0351 |
Onchocerca volvulus | Hexokinase homolog | 0.0264 | 0.139 | 0.5263 |
Plasmodium vivax | adenosylhomocysteinase(S-adenosyl-L-homocystein e hydrolase), putative | 0.1344 | 1 | 1 |
Schistosoma mansoni | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.1344 | 1 | 1 |
Loa Loa (eye worm) | adenosylhomocysteinase | 0.1344 | 1 | 1 |
Trichomonas vaginalis | adenosylhomocysteinase, putative | 0.1344 | 1 | 1 |
Toxoplasma gondii | S-Adenosyl homocysteine hydrolase | 0.1344 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0205 | 0.0915 | 0.0915 |
Treponema pallidum | hexokinase (hxk) | 0.0421 | 0.2642 | 1 |
Schistosoma mansoni | adenosylhomocysteinase | 0.0832 | 0.5915 | 0.5915 |
Brugia malayi | Hexokinase family protein | 0.0264 | 0.139 | 0.139 |
Brugia malayi | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Schistosoma mansoni | adenosylhomocysteinase | 0.1344 | 1 | 1 |
Plasmodium falciparum | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Echinococcus granulosus | hexokinase type 2 | 0.0421 | 0.2642 | 0.2642 |
Mycobacterium leprae | putative S-adenosyl-L-homocysteine hydrolase SahH | 0.1344 | 1 | 1 |
Loa Loa (eye worm) | hexokinase type II | 0.0421 | 0.2642 | 0.2642 |
Onchocerca volvulus | 0.0264 | 0.139 | 0.5263 | |
Loa Loa (eye worm) | hexokinase | 0.013 | 0.0322 | 0.0322 |
Leishmania major | hexokinase, putative | 0.0421 | 0.2642 | 0.2642 |
Loa Loa (eye worm) | hypothetical protein | 0.0134 | 0.0351 | 0.0351 |
Echinococcus granulosus | adenosylhomocysteinase | 0.1344 | 1 | 1 |
Mycobacterium ulcerans | S-adenosyl-L-homocysteine hydrolase | 0.1344 | 1 | 1 |
Echinococcus multilocularis | hexokinase type 2 | 0.0421 | 0.2642 | 0.2642 |
Echinococcus multilocularis | adenosylhomocysteinase | 0.1344 | 1 | 1 |
Mycobacterium tuberculosis | Probable adenosylhomocysteinase SahH (S-adenosyl-L-homocysteine hydrolase) (adohcyase) | 0.1344 | 1 | 1 |
Entamoeba histolytica | hexokinase 1 | 0.0421 | 0.2642 | 0.2642 |
Echinococcus multilocularis | hexokinase | 0.0421 | 0.2642 | 0.2642 |
Trypanosoma cruzi | S-adenosylhomocysteine hydrolase, putative | 0.1344 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.206 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.1961 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 10 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 10.4179 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.